Cabaletta’s CAR T-cell therapy cleared for SLE Phase 1/2 trial
The U.S. Food and Drug Administration (FDA) has cleared a Phase 1/2 clinical trial to test CABA-201, Cabaletta Bio’s investigational CAR T-cell therapy, in people with systemic lupus erythematosus (SLE) with or without kidney involvement. Cabaletta asked to launch the trial in the form of an investigational new…